



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C07D 207/00, 401/00, C07K 5/00</b>	<b>A2</b>	<b>(11) International Publication Number:</b> <b>WO 98/19998</b> <b>(43) International Publication Date:</b> 14 May 1998 (14.05.98)
<b>(21) International Application Number:</b> PCT/EP97/06125 <b>(22) International Filing Date:</b> 5 November 1997 (05.11.97)  <b>(30) Priority Data:</b> 08/746,295      7 November 1996 (07.11.96)      US  <b>(71) Applicant (for all designated States except US):</b> NOVARTIS AG [CH/CH]; Schwarzwaldallee 215, CH-4058 Basel (CH).  <b>(72) Inventor; and</b> <b>(75) Inventor/Applicant (for US only):</b> VILLHAUER, Edwin, Bernard [US/US]; 20 Dorothy Drive, Morristown, NJ 07960 (US).  <b>(74) Agent:</b> ROTH, Bernhard, M.; Novartis AG, Patent- und Markenabteilung, Lichtstrasse 35, CH-4002 Basel (CH).		<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>Without international search report and to be republished upon receipt of that report.</i>
<b>(54) Title:</b> N-SUBSTITUTED 2-CYANOPYRROLIDINES  <b>(57) Abstract</b> <p>N-(N'-substituted glycy)-2-cyanopyrrolidines, e.g. the compounds of formula (I) wherein R has various significances, are novel. They inhibit DPP-IV (dipeptidyl-peptidase-IV) activity. They are therefore indicated for use as pharmaceuticals in inhibiting DPP-IV and in the treatment of conditions mediated by DPP-IV, such as non-insulin-dependent diabetes mellitus, arthritis, obesity, osteoporosis and further conditions of impaired glucose tolerance.</p> <div style="text-align: center;"> <p style="text-align: right;">(I)</p> </div>		

17  
17  
34

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NI	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

## N-SUBSTITUTED 2-CYANOPYRROLIDINES

### Field

The present invention relates to N-substituted 2-cyanopyrrolidines. More particularly, it provides novel N-glycyl-2-cyanopyrrolidine derivatives.

### Background

Dipeptidyl peptidase-IV (**DPP-IV**) is a serine protease which cleaves N-terminal dipeptides from a peptide chain containing, preferably, a proline residue in the penultimate position. Although the biological role of DPP-IV in mammalian systems has not been completely established, it is believed to play an important role in neuropeptide metabolism, T-cell activation, attachment of cancer cells to the endothelium and the entry of HIV into lymphoid cells. DPP-IV is responsible for inactivating glucagon-like peptide-1 (**GLP-1**). More particularly, DPP-IV cleaves the amino-terminal His-Ala dipeptide of GLP-1, generating a GLP-1 receptor antagonist, and thereby shortens the physiological response to GLP-1. Since the half-life for DPP-IV cleavage is much shorter than the half-life for removal of GLP-1 from circulation, a significant increase in GLP-1 bioactivity (5- to 10-fold) is anticipated from DPP-IV inhibition. Since GLP-1 is a major stimulator of pancreatic insulin secretion and has direct beneficial effects on glucose disposal, DPP-IV inhibition appears to represent an attractive approach for treating non-insulin-dependent diabetes mellitus (**NIDDM**).


Although a number of DPP-IV inhibitors have been described, all have limitations relating to potency, stability or toxicity. Accordingly, a great need exists for novel DPP-IV inhibitors which are useful in treating conditions mediated by DPP-IV inhibition and which do not suffer from the above-mentioned limitations.

**Summary of the invention**

The invention provides novel N-(N'-substituted glycy)-2-cyanopyrrolidines which are effective as DPP-IV inhibitors in treating conditions mediated by DPP-IV. It also concerns corresponding pharmaceutical compositions, a process for their preparation, a method of inhibiting DPP-IV comprising administering to a patient in need of such treatment a therapeutically effective amount thereof, the compounds for use as a pharmaceutical, and their use in a process for the preparation of a medicament for treating a condition mediated by DPP-IV.

**Detailed description**

The invention concerns N-(N'-substituted glycy)-2-cyanopyrrolidines, hereinafter briefly named "**the compounds of the invention**"; more particularly, it concerns compounds of formula I:



wherein R is:

a)  $R_1R_{1a}N(CH_2)_m$  wherein

$R_1$  is a pyridinyl or pyrimidinyl moiety optionally mono- or independently disubstituted with  $(C_{1-4})$ alkyl,  $(C_{1-4})$ alkoxy, halogen, trifluoromethyl, cyano or nitro; or phenyl optionally mono- or independently disubstituted with  $(C_{1-4})$ alkyl,  $(C_{1-4})$ alkoxy or halogen;

$R_{1a}$  is hydrogen or  $(C_{1-8})$ alkyl; and

m is 2 or 3;

b)  $(C_{3-12})$ cycloalkyl optionally monosubstituted in the 1-position with  $(C_{1-3})$ hydroxyalkyl;

c)  $R_2(CH_2)_n$  wherein either

$R_2$  is phenyl optionally mono- or independently di- or independently trisubstituted with  $(C_{1-4})$ alkyl,  $(C_{1-4})$ alkoxy, halogen or phenylthio optionally monosubstituted in the phenyl ring with hydroxymethyl; or is  $(C_{1-8})$ alkyl; a [3.1.1]bicyclic carbocyclic moiety optionally mono- or plurisubstituted with  $(C_{1-8})$ alkyl;

- a pyridinyl or naphthyl moiety optionally mono- or independently disubstituted with (C<sub>1-4</sub>)alkyl, (C<sub>1-4</sub>)alkoxy or halogen; cyclohexene; or adamantyl; and  
n is 1 to 3; or  
R<sub>2</sub> is phenoxy optionally mono- or independently disubstituted with (C<sub>1-4</sub>)alkyl, (C<sub>1-4</sub>)alkoxy or halogen; and  
n is 2 or 3;
- d) (R<sub>3</sub>)<sub>2</sub>CH(CH<sub>2</sub>)<sub>2</sub>- wherein each R<sub>3</sub> independently is phenyl optionally mono- or independently disubstituted with (C<sub>1-4</sub>)alkyl, (C<sub>1-4</sub>)alkoxy or halogen;
- e) R<sub>4</sub>(CH<sub>2</sub>)<sub>p</sub>- wherein R<sub>4</sub> is 2-oxopyrrolidinyl or (C<sub>2-4</sub>)alkoxy and  
p is 2 to 4;
- f) isopropyl optionally monosubstituted in 1-position with (C<sub>1-3</sub>)hydroxyalkyl;
- g) R<sub>5</sub> wherein R<sub>5</sub> is: indanyl; a pyrrolidinyl or piperidinyl moiety optionally substituted with benzyl; a [2.2.1]- or [3.1.1]bicyclic carbocyclic moiety optionally mono- or plurisubstituted with (C<sub>1-8</sub>)alkyl; adamantyl; or (C<sub>1-8</sub>)alkyl optionally mono- or independently plurisubstituted with hydroxy, hydroxymethyl or phenyl optionally mono- or independently disubstituted with (C<sub>1-4</sub>)alkyl, (C<sub>1-4</sub>)alkoxy or halogen;
- in free form or in acid addition salt form.

The compounds of formula I can exist in free form or in acid addition salt form. Salt forms may be recovered from the free form in known manner and vice-versa. Acid addition salts may e.g. be those of pharmaceutically acceptable organic or inorganic acids. Although the preferred acid addition salts are the hydrochlorides, salts of methanesulfonic, sulfuric, phosphoric, citric, lactic and acetic acid may also be utilized.

The compounds of the invention may exist in the form of optically active isomers or diastereoisomers and can be separated and recovered by conventional techniques, such as chromatography.

"Alkyl" and "alkoxy" are either straight or branched chain, of which examples of the latter are isopropyl and tert-butyl.

R preferably is a), b) or e) as defined above. R<sub>1</sub> preferably is a pyridinyl or pyrimidinyl moiety optionally substituted as defined above. R<sub>1a</sub> preferably is hydrogen. R<sub>2</sub> preferably is phenyl optionally substituted as defined above. R<sub>3</sub> preferably is unsubstituted phenyl.

R<sub>4</sub> preferably is alkoxy as defined above. R<sub>5</sub> preferably is optionally substituted alkyl as defined above. m preferably is 2. n preferably is 1 or 2, especially 2. p preferably is 2 or 3, especially 3.

Pyridinyl preferably is pyridin-2-yl; it preferably is unsubstituted or monosubstituted, preferably in 5-position. Pyrimidinyl preferably is pyrimidin-2-yl. It preferably is unsubstituted or monosubstituted, preferably in 4-position. Preferred as substituents for pyridinyl and pyrimidinyl are halogen, cyano and nitro, especially chlorine.

When it is substituted, phenyl preferably is monosubstituted; it preferably is substituted with halogen, preferably chlorine, or methoxy. It preferably is substituted in 2-, 4- and/or 5-position, especially in 4-position.

(C<sub>3-12</sub>)cycloalkyl preferably is cyclopentyl or cyclohexyl. When it is substituted, it preferably is substituted with hydroxymethyl. (C<sub>1-4</sub>)alkoxy preferably is of 1 or 2 carbon atoms, it especially is methoxy. (C<sub>2-4</sub>)alkoxy preferably is of 3 carbon atoms, it especially is isopropoxy. Halogen is fluorine, chlorine, bromine or iodine, preferably fluorine, chlorine or bromine, especially chlorine. (C<sub>1-8</sub>)alkyl preferably is of 1 to 6, preferably 1 to 4 or 3 to 5, especially of 2 or 3 carbon atoms, or methyl. (C<sub>1-4</sub>) alkyl preferably is methyl or ethyl, especially methyl. (C<sub>1-3</sub>)hydroxyalkyl preferably is hydroxymethyl.

A [3.1.1]bicyclic carbocyclic moiety optionally substituted as defined above preferably is bicyclo[3.1.1]hept-2-yl optionally disubstituted in 6-position with methyl, or bicyclo[3.1.1]hept-3-yl optionally trisubstituted with one methyl in 2-position and two methyl groups in 6-position. A [2.2.1]bicyclic carbocyclic moiety optionally substituted as defined above preferably is bicyclo[2.2.1]hept-2-yl.

Naphthyl preferably is 1-naphthyl. Cyclohexene preferably is cyclohex-1-en-1-yl. Adamantyl preferably is 1- or 2-adamantyl.

A pyrrolidinyl or piperidinyl moiety optionally substituted as defined above preferably is pyrrolidin-3-yl or piperidin-4-yl. When it is substituted it preferably is N-substituted.

A preferred group of compounds of the invention is the compounds of formula I wherein R is R' (**compounds Ia**), whereby R' is:

- R<sub>1</sub>'NH(CH<sub>2</sub>)<sub>2</sub>- wherein R<sub>1</sub>' is pyridinyl optionally mono- or independently disubstituted with halogen, trifluoromethyl, cyano or nitro; or unsubstituted pyrimidinyl;
  - (C<sub>3-7</sub>)cycloalkyl optionally monosubstituted in 1-position with (C<sub>1-3</sub>)hydroxyalkyl;
  - R<sub>4</sub>'(CH<sub>2</sub>)<sub>3</sub>- wherein R<sub>4</sub>' is (C<sub>2-4</sub>)alkoxy; or
  - R<sub>5</sub>, wherein R<sub>5</sub> is as defined above;
- in free form or in acid addition salt form.

More preferred compounds of the invention are those compounds of formula I wherein R is R'' (**compounds Ib**), whereby R'' is:

- R<sub>1</sub>''NH(CH<sub>2</sub>)<sub>2</sub>- wherein R<sub>1</sub>'' is pyridinyl mono- or independently disubstituted with halogen, trifluoromethyl, cyano or nitro;
  - (C<sub>4-6</sub>)cycloalkyl monosubstituted in 1-position with (C<sub>1-3</sub>)hydroxyalkyl;
  - R<sub>4</sub>'(CH<sub>2</sub>)<sub>3</sub>- wherein R<sub>4</sub>' is as defined above; or
  - R<sub>5</sub>' wherein R<sub>5</sub>' is a [2.2.1]- or [3.1.1]bicyclic carbocyclic moiety optionally mono- or plurisubstituted with (C<sub>1-8</sub>)alkyl; or adamantyl;
- in free form or in acid addition salt form.

Even more preferred compounds of the invention are the compounds of formula I wherein R is R''' (**compounds Ic**), whereby R''' is:

- R<sub>1</sub>'''NH(CH<sub>2</sub>)<sub>2</sub>- wherein R<sub>1</sub>''' is as defined above;
  - (C<sub>4-6</sub>)cycloalkyl monosubstituted in 1-position with hydroxymethyl;
  - R<sub>4</sub>'(CH<sub>2</sub>)<sub>3</sub>- wherein R<sub>4</sub>' is as defined above; or
  - R<sub>5</sub>'' wherein R<sub>5</sub>'' is adamantyl;
- in free form or in acid addition salt form.

A further group of compounds of the invention is **compounds Ip**, wherein R is  $R^p$ , which is:

- a)  $R_1^p NH(CH_2)_2$ - wherein  $R_1^p$  is a pyridinyl or pyrimidinyl moiety optionally mono- or independently disubstituted with halogen, trifluoromethyl, cyano or nitro;
- b)  $(C_{3-7})$ cycloalkyl optionally monosubstituted in 1-position with  $(C_{1-3})$ hydroxyalkyl;
- c)  $R_2^p(CH_2)_2$ - wherein  $R_2^p$  is phenyl optionally mono- or independently di- or independently trisubstituted with halogen or  $(C_{1-3})$ alkoxy;
- d)  $(R_3^p)_2CH(CH_2)_2$ - wherein each  $R_3^p$  independently is phenyl optionally monosubstituted with halogen or  $(C_{1-3})$ alkoxy;
- e)  $R_4(CH_2)_3$ - wherein  $R_4$  is as defined above; or
- f) isopropyl optionally monosubstituted in 1-position with  $(C_{1-3})$ hydroxyalkyl; in free form or in pharmaceutically acceptable acid addition salt form.

A further group of compounds of the invention is **compounds Is**, wherein R is  $R^s$ , which is:


- a)  $R_1^s R_{1a}^s (CH_2)_{ms}$ - wherein  $R_1^s$  is pyridinyl optionally mono- or independently disubstituted with chlorine, trifluoromethyl, cyano or nitro; pyrimidinyl optionally monosubstituted with chlorine or trifluoromethyl; or phenyl;  
 $R_{1a}^s$  is hydrogen or methyl; and  
 $ms$  is 2 or 3;
- b)  $(C_{3-12})$ cycloalkyl optionally monosubstituted in 1-position with hydroxymethyl;
- c)  $R_2^s(CH_2)_{ns}$ - wherein either  
 $R_2^s$  is phenyl optionally mono- or independently di- or independently trisubstituted with halogen, alkoxy of 1 or 2 carbon atoms or phenylthio monosubstituted in the phenyl ring with hydroxymethyl;  
 $(C_{1-6})$ alkyl; 6,6-dimethylbicyclo[3.1.1]hept-2-yl; pyridinyl; naphthyl; cyclohexene; or adamantyl; and  $ns$  is 1 to 3; or  
 $R_2^s$  is phenoxy; and  $ns$  is 2;
- d) (3,3-diphenyl)propyl;



-7-

- e)  $R_4^s(CH_2)_{ps}$  wherein  $R_4^s$  is 2-oxopyrrolidin-1-yl or isopropoxy and  $ps$  is 2 or 3;
- f) isopropyl optionally monosubstituted in 1-position with hydroxymethyl;
- g)  $R_5^s$  wherein  $R_5^s$  is: indanyl; a pyrrolidinyl or piperidinyl moiety optionally N-substituted with benzyl; bicyclo[2.2.1]hept-2-yl; 2,6,6-trimethylbicyclo[3.1.1]hept-3-yl; adamantyl; or  $(C_{1-8})$ alkyl optionally mono- or independently disubstituted with hydroxy, hydroxymethyl or phenyl; in free form or in acid addition salt form.

The compounds of the invention may be prepared by a process which comprises coupling a reactive (2-cyanopyrrolidino)carbonylmethylene compound with an appropriate substituted amine; more particularly, for the preparation of the compounds of formula I it comprises reacting a compound of formula II



wherein X is a reactive group,  
with a compound of formula III



wherein R is as defined above,  
and recovering the resultant compound of formula I in free form or in acid addition salt form.

X preferably is a halogen such as bromine, chlorine or iodine.


The process of the invention may be effected in conventional manner.

The compound of formula II is preferably reacted with at least 3 equivalents of a primary amine of formula III. The reaction is conveniently conducted in the presence of an inert, organic solvent, preferably a cyclic ether such as tetrahydrofuran. The temperature preferably is of from about 0° to about 35°C, preferably between about 0° and about 25°C.

The compounds of the invention may be isolated from the reaction mixture and purified in conventional manner, e.g. by chromatography.

The starting materials may also be prepared in conventional manner.

The compounds of formula II may e.g. be prepared by the following two-step reaction scheme:



Step 1 involves the reaction of the pyrrolidine of formula IV with a slight molar excess of a haloacetylhalide such as bromoacetyl bromide or chloroacetyl chloride and triethylamine and a catalytic amount of dimethylaminopyridine (DMAP). The reaction conveniently is conducted in the presence of an inert, organic solvent, preferably a chlorinated, aliphatic hydrocarbon such as methylene chloride, at a temperature of from about 0° to about 25°C, preferably at a temperature between about 0° and about 15°C.

Step 2 concerns the dehydration of the compound of formula V, prepared in Step 1, with at least 2 equivalents of trifluoroacetic anhydride (TFAA). The dehydration preferably is conducted in the presence of an inert, organic solvent such as tetrahydrofuran or a chlorinated, aliphatic hydrocarbon such as methylene chloride, at a temperature of from about 0° to about 25°C, preferably at a temperature between about 0° and about 15°C.

Insofar as its preparation is not particularly described herein, a compound used as starting material is known or may be prepared from known compounds in known manner or analogously to known methods or analogously to methods described in the Examples.

The following Examples illustrate the invention. All temperatures are in degrees Celsius.

**Example 1: 1-[2-[(5-Chloropyridin-2-yl)amino]ethylamino]acetyl-2-cyano-(S)-pyrrolidine**

To a 500 ml flask is added 16.6 g of 2-[(5-chloropyridin-2-yl)amino]ethylamine and 100 ml of tetrahydrofuran and the mixture is cooled in an ice bath. To the cooled mixture is added 7.0 g of (2-cyanopyrrolidino)carbonylmethylene-(S)-bromide dissolved in 30 ml of tetrahydrofuran. The resultant mixture is stirred for 2 hours at 0°, the solvent is removed by rotovaping and the mixture is partitioned between ethyl acetate and water. The product is then extracted into the ethyl acetate layer and the aqueous layer is then washed twice with ethyl acetate. The combined organic layers are washed successively with water and brine, dried over sodium sulfate and concentrated to obtain the desired free base compound in crude form. The crude form is then purified on silica gel employing a mixture of 5% methanol in methylene chloride as the eluent to yield the **title compound in free base form** as a light brown oil.

After dissolving the **free base** in 30 ml of dry tetrahydrofuran, **hydrogen chloride** gas is bubbled into the solution for five seconds. The off-white precipitate that forms is filtered, washed with dry tetrahydrofuran and the solvent is removed by high vacuum pumping to obtain the **title compound in dihydrochloride acid addition salt form** (off-white solid; m.p. 265°-267°; NMR: see \* at bottom of Table hereunder).

The starting material is obtained as follows:

a) 22.37 g of (S)-2-carbamoylpyrrolidine, 30.1 ml of triethylamine and 30.0 mg of dimethylaminopyridine (DMAP) are dissolved in 200 ml of methylene chloride and the solution is then added, dropwise, to an ice-cold solution of 18.8 ml of bromoacetyl bromide in 192 ml of methylene chloride, over a period of 60 minutes under a calcium sulfate drying tube. The resultant solution is stirred for 2 hours at ice-water temperature under a calcium sulfate drying tube, then poured into 3.5 liters of ethyl acetate. The resultant precipitate is filtered, washed with ethyl acetate, and the filtrate is concentrated to obtain (2-carbamoylpyrrolidino)-carbonylmethylene-(S)-bromide (hard yellow taffy).

-10-

b) 50.0 g of the **bromide compound** prepared in a) above is dissolved in 300 ml of methylene chloride and the solution is cooled in an ice water bath under a calcium sulfate drying tube. The cooled solution is then poured into 60.2 ml of **trifluoroacetic anhydride** over a 2 minute period, the resultant solution is stirred at ice-water temperature under a calcium sulfate drying tube for 4 hours, and partitioned between methylene chloride and saturated aqueous sodium bicarbonate. The product is extracted into the methylene chloride layer and the aqueous layer is washed twice with methylene chloride. The combined organic layers are washed successively with water and brine and then dried over sodium sulfate. The solution is filtered and the solvent is removed by rotovaping and high vacuum pumping to obtain **(2-cyanopyrrolidino)carbonylmethylene-(S)-bromide** (dark yellow solid).

The following compounds of the invention, of formula I, are obtained in analogous manner by reacting a corresponding compound of formula II with a corresponding compound of formula III (in the following Table, where only an acid addition salt form of a compound of the invention is mentioned, the compound is recovered from the free base without isolation thereof):

Example No.	R	Form	Analogously to Ex. No.	Characterization data
2	2-[(5-CF <sub>3</sub> -pyridin-2-yl)amino]ethyl	b	1 <sup>1)</sup>	golden oil; NMR*
3	2-[(5-cyanopyridin-2-yl)amino]ethyl	b	1	golden oil
		dch	1	off-white precipitate, m.p. 155-157°; NMR*; [ $\alpha$ ] <sub>D</sub> <sup>20</sup> = -77.2° (c=0.012, MeOH)
4	2-[(pyrimidin-2-yl)amino]ethyl	b	2 <sup>1a)</sup>	golden oil; NMR*
5	(1-hydroxymethyl)cyclopent-1-yl	b	1 <sup>2)</sup>	yellow solid; m.p. 65-67°; NMR*
6	2-[(pyridin-2-yl)amino]ethyl	b	2 <sup>3)</sup>	golden oil; NMR*
7A	2-[(4-chloropyrimidin-2-yl)amino]ethyl	b	2	tan solid; NMR*
7B	2-[(3-chloropyridin-2-yl)amino]ethyl	b	2	golden oil; NMR*
7C	2-[(4-CF <sub>3</sub> -pyrimidin-2-yl)amino]ethyl	b	2	golden oil; NMR*
7D	2-(2-chlorophenyl)ethyl	b	2	NMR*
7E	(3,3-diphenyl)propyl	b	2	NMR*
8	2-[(5-nitropyridin-2-yl)amino]ethyl	b	5 <sup>3a)</sup>	bright yellow thick oil; NMR*
9A	2-[(3-chloro-5-CF <sub>3</sub> -pyridin-2-yl)amino]ethyl	b	2 <sup>3b)</sup>	golden oil; NMR*
9B	2-[(3-CF <sub>3</sub> -pyridin-2-yl)amino]ethyl	b	2 <sup>3b)</sup>	golden oil; NMR*
9C	2-[(3,5-dichloropyridin-2-yl)amino]ethyl	b	2 <sup>3b)</sup>	golden oil; NMR*
10	cyclopent-1-yl	b	2	tan solid
11	2-(2-bromo-4,5-dimethoxyphenyl)ethyl	ch	1	white solid; NMR*
12	3-(isopropoxy)propyl	b	5 <sup>3a)</sup>	clear light yellow, thick oil; NMR*
		b	1	brown oil
		ch	1	white solid, m.p. 174-176°; NMR*

Example No.	R	Form	Analogously to Ex. No.	Characterization data
13	2-hydroxy-1,1-dimethylethyl	b	2 <sup>d)</sup>	golden oil
14	3-(2-oxopyrrolidin-1-yl)propyl	ch	1	brown solid; NMR*
15	1-hydroxymethylcyclohexyl	b	2 <sup>e)</sup>	golden oil
16	2-(4-ethoxyphenyl)ethyl	ch	1	tan solid; NMR*
17	1-phenylmethyl-3-(R)-pyrrolidinyl	b	1 <sup>6)</sup>	yellow waxy solid; m.p. 93°; <sup>13</sup> C-NMR: 118.1 (ppm)
18	2-(4-methoxyphenyl)ethyl	ch	1	white solid; m.p. 182-184°; <sup>13</sup> C-NMR: 121.4 (ppm)
19	2-(3-methoxyphenyl)ethyl	dch	1 <sup>7)</sup>	off-white solid; m.p. 175-177°; <sup>13</sup> C-NMR: 121.5 (ppm)
20	(1-naphthalenyl)methyl	ch	1	white solid; m.p. 185-187°; <sup>13</sup> C-NMR: 121.4 (ppm)
21	3-phenylpropyl	ch	1	light yellow solid; m.p. 172-174°; <sup>13</sup> C-NMR: 119.25 (ppm)
22	3-[(phenyl)(methyl)amino]propyl	ch	1	light yellow solid; m.p. 130-135°; <sup>13</sup> C-NMR: 119.29 (ppm)
23	2-(3,4-dimethoxyphenyl)ethyl	ch	1	off-white fluffy solid; <sup>13</sup> C-NMR: 119.26 (ppm)
24	cycloheptyl	ch	1	white solid; m.p. 96-98° (foams); <sup>13</sup> C-NMR: 121.6 (ppm)
25	[1S[1 $\alpha$ ,2 $\alpha$ (S*),5 $\alpha$ ]]-(6,6-dimethylbicyclo[3.1.1]-hept-2-yl)methyl	dch	1	white solid; m.p. 170-172°; <sup>13</sup> C-NMR: 121.5 (ppm)
26	2-(2,5-dimethoxyphenyl)ethyl	ch	1 <sup>8)</sup>	white solid; m.p. 275-279° (dec.); <sup>13</sup> C-NMR: 119.17 (ppm)
27	2-(1-cyclohexen-1-yl)ethyl	ch	1	white fluffy solid; m.p. 65-67°; <sup>13</sup> C-NMR: 119.25 (ppm)
28	cyclohexyl	ch	1	off-white fluffy solid; m.p. 162-164°; <sup>13</sup> C-NMR: 119.27 (ppm)
29	[1S[1 $\alpha$ , 2 $\alpha$ (S*),5 $\alpha$ ]]-bicyclo[2.2.1]hept-2-yl	ch	1	white fluffy solid; m.p. 182-184°; <sup>13</sup> C-NMR: 119.28 (ppm)
30	2-(2-pyridinyl)ethyl	ch	1 <sup>9)</sup>	white solid; m.p. 98-100°; <sup>13</sup> C-NMR: 118.36 (ppm)
31	(2-phenylamino)ethyl	dch	1	white solid; m.p. 95-97°; <sup>13</sup> C-NMR: 121.5 (ppm)
32	3,3-dimethylbutyl	dch	1	white solid; m.p. 124-126°; <sup>13</sup> C-NMR: 121.4 (ppm)
33	[1S[1 $\alpha$ ,2 $\beta$ ,3 $\alpha$ (S*),5 $\alpha$ ]]-2,6,6-trimethylbicyclo[3.1.1]-hept-3-yl	ch	1 <sup>10)</sup>	white solid; m.p. 164-166°; <sup>13</sup> C-NMR: 121.5 (ppm)
				white solid; m.p. 82-84°; <sup>13</sup> C-NMR: 121.5 (ppm)

Example No.	R	Form	Analogously to Ex. No.	Characterization data
34	[S,S]-(1-hydroxymethyl)propyl	ch	1 <sup>(11)</sup>	off-white solid; m.p. 80-82°; <sup>13</sup> C-NMR: 118.2 (ppm)
35	[2-[(2-hydroxymethyl)phenyl]thio]phenylmethyl	ch	1 <sup>(12)</sup>	yellow solid; m.p. 65-67°; <sup>13</sup> C-NMR: 121.4 (ppm)
36	2-(2-methoxyphenyl)ethyl	ch	1	off-white solid; m.p. 174-176°; <sup>13</sup> C-NMR: 121.7 (ppm)
37	5-hydroxypentyl	ch	1	sticky light-green solid; <sup>13</sup> C-NMR: 121.67 (ppm)
38	cyclobutyl	ch	1	off-white solid; m.p. 274-278° (dec.); <sup>13</sup> C-NMR: 121.64 (ppm)
39	2-(2,4-dichlorophenyl)ethyl	ch	1	white fluffy solid; m.p. 154-156°; <sup>13</sup> C-NMR: 121.48 (ppm)
40	1-(S)-(+)-hydroxymethyl-3-methylbutyl	ch	1 <sup>(13)</sup>	light yellow solid; m.p. 65-66°; <sup>13</sup> C-NMR: 117.99 (ppm)
41	[1R*,2S*]-2-hydroxy-2-phenylethyl	ch	1 <sup>(14)</sup>	light yellow solid; m.p. 82-83°; <sup>13</sup> C-NMR: 118.35 (ppm)
42	2-(2-fluorophenyl)ethyl	ch	1	white fluffy solid; m.p. 160-162°; <sup>13</sup> C-NMR: 121.70 (ppm)
43	cyclopropyl	ch	1	off-white solid; m.p. 170-172°; <sup>13</sup> C-NMR: 121.62 (ppm)
44	[1S(1S,2S,3S,5R)]-2,6,6-trimethylbicyclo-[3.1.1]hept-3-yl	ch	1 <sup>(15)</sup>	white solid; m.p. 84-86°; <sup>13</sup> C-NMR: 121.8 (ppm)
45	(2-phenoxy)ethyl	ch	1	sticky golden solid; <sup>13</sup> C-NMR: 121.7 (ppm)
46	2-(3,5-dimethoxyphenyl)ethyl	ch	1	white fluffy solid; m.p. 74-76°; <sup>13</sup> C-NMR: 121.66 (ppm)
47	1-adamantyl	ch	1	white solid; m.p. 240-242°; <sup>13</sup> C-NMR: 121.80 (ppm)
48	1,1,3,3-tetramethylbutyl	ch	1	white fluffy solid; m.p. 68-70°; <sup>13</sup> C-NMR: 121.55 (ppm)
49	2-adamantyl	ch	1	off-white solid; m.p. 122-124°; <sup>13</sup> C-NMR: 121.69 (ppm)
50	1,1-dimethylpropyl	ch	1	white fluffy solid; m.p. 62-64°; <sup>13</sup> C-NMR: 121.53 (ppm)
51	benzyl	ch	1	white solid; m.p. 58-60°; <sup>13</sup> C-NMR: 121.38 (ppm)
52	1,1-dimethylethyl	ch	1	white solid; m.p. 226-228°; <sup>13</sup> C-NMR: 121.56 (ppm)
53	(2-adamantyl)methyl	ch	1	white solid; m.p. 158-160°; <sup>13</sup> C-NMR: 121.53 (ppm)
54	2-phenylethyl	ch	1	white solid; m.p. 275-280° (dec.); <sup>13</sup> C-NMR: 121.52 (ppm)
55	pentyl	ch	1	white solid; m.p. 176-178°; <sup>13</sup> C-NMR: 121.67 (ppm)
56	butyl	ch	1	white solid; m.p. 180-182°; <sup>13</sup> C-NMR: 121.53 (ppm)

Example No.	R	Form	Analogously to Ex. No.	Characterization data
57	cyclododecyl	ch	1	white fluffy solid; <sup>13</sup> C-NMR: 121.52 (ppm)
58	cyclooctyl	ch	1	white fluffy solid; <sup>13</sup> C-NMR: 121.64 (ppm)
59	propyl	ch	1	white solid; m.p. 193-194°; <sup>13</sup> C-NMR: 121.57 (ppm)
60	ethyl	ch	1	off-white sticky solid; <sup>13</sup> C-NMR: 121.67 (ppm)
61	heptyl	ch	1	white solid; m.p. 170-172°; <sup>13</sup> C-NMR: 121.7 (ppm)
62	hexyl	ch	1	white solid; m.p. 174-176°; <sup>13</sup> C-NMR: 121.75 (ppm)
63	3-[(5-cyano-2-pyridinyl)amino]propyl	dch	1 <sup>6)</sup>	white sticky solid; m.p. 210-212°; <sup>13</sup> C-NMR: 119.33 (ppm)
64	1-ethylpropyl	ch	1	white fluffy sticky solid; <sup>13</sup> C-NMR: 119.35 (ppm)
65	2,3-dihydro-1H-inden-2-yl	ch	1	white solid; m.p. 182-184°; <sup>13</sup> C-NMR: 121.38 (ppm)
66	1-benzylpiperidin-4-yl	ch	1	white solid; m.p. 280-283° (dec.); <sup>13</sup> C-NMR: 121.39 (ppm)

b = in free base form    ch = in monohydrochloride form;    dch = in dihydrochloride form  
 dec. = decomposes;    m.p. = melting point

- 1) starting from 2-[5-(5-trifluoromethylpyridin-2-yl)amino]ethylamine in tetrahydrofuran, using 5 % methanol in methylene chloride as eluent
- 1a) using 10 % methanol in methylene chloride as eluent
- 2) reacting (1-hydroxymethyl)cyclopentylamine in anhydrous tetrahydrofuran for 18 h at room temperature under a calcium sulfate drying tube
- 3) using methylene chloride, methanol and ammonium hydroxide 90:10:0.5 as eluent
- 3a) using flash chromatography, employing a mixture of 5 % methanol in methylene chloride as eluent
- 3b) using 3 % methanol in methylene chloride as eluent
- 4) using methylene chloride, methanol and ammonium hydroxide 80:20:1 as eluent
- 5) using methylene chloride, methanol and ammonium hydroxide 90:10:1 as eluent
- 6) reacting (1-aminocyclohexane)methanol in tetrahydrofuran with 1-chloroacetyl-2-(S)-cyanopyrrolidine (prepared from chloroacetylchloride and L-prolinamide and reaction of the resultant product with trifluoroacetic anhydride) at ice-temperature under a calcium sulfate drying tube, and purifying the reaction mixture on silicagel employing 5 % methanol in methylene chloride as eluent



- 7) using (3R)-(-)-1-benzyl-3-aminopyrrolidine as starting material
- 8) using (-)-cis-myrtaniline as starting material
- 9) using (+/-)-exo-2-aminobornane as starting material
- 10) using (1R,2R,3R,5S)-(-)-isopinocampheylamine as starting material
- 11) using (S)-(+)-2-amino-1-butanol as starting material
- 12) using 2-(2-aminomethyl)phenylthio)benzyl alcohol as starting material
- 13) using (S)-(+)-leucinol as starting material
- 14) using (1R,2S)-(-)-norephedrine as starting material
- 15) using (1S,2S,3S,5R)-(+)-isopinocampheylamine as starting material
- 16) using 2-(3-aminopropylamino)-5-cyanopyridine as starting material

\* NMR:

Compound #	<sup>13</sup> C-NMR (MHz, solvent) d ppm (CN)
Ex. 5	<sup>13</sup> C NMR (75 MHz, CD <sub>3</sub> OD) d 119.64 ppm (CN)
Ex. 12	<sup>13</sup> C NMR (75 MHz, D <sub>2</sub> O) d 121.63 ppm (CN)
Ex. 1	<sup>13</sup> C NMR (75 MHz, D <sub>2</sub> O) d 121.60 ppm (CN)
Ex. 3	<sup>13</sup> C NMR (75 MHz, D <sub>2</sub> O) d 120.42 ppm (CN)
Ex. 8	<sup>13</sup> C NMR (75 MHz, DMSO) d 119.13 ppm (CN)
Ex. 7B	<sup>13</sup> C NMR (75 MHz, CDCl <sub>3</sub> ) d 118.23 ppm (CN)
Ex. 9A	<sup>13</sup> C NMR (75 MHz, CD <sub>3</sub> OD) d 119.68 ppm (CN)
Ex. 9B	<sup>13</sup> C NMR (75 MHz, CD <sub>3</sub> OD) d 119.66 ppm (CN)

Compound #	<sup>13</sup> C NMR (MHz, solvent) d ppm (CN)
Ex. 9C	<sup>13</sup> C NMR (75 MHz, CD <sub>3</sub> OD) d 119.68 ppm (CN)
Ex. 6	<sup>13</sup> C NMR (75 MHz, CD <sub>3</sub> OD) d 119.84 ppm (CN)
Ex. 7C	<sup>13</sup> C NMR (75 MHz, CDCl <sub>3</sub> ) d 118.23 ppm (CN)
Ex. 2	<sup>13</sup> C NMR (75 MHz, CD <sub>3</sub> OD) d 119.68 ppm (CN)
Ex. 7A	<sup>13</sup> C NMR (75 MHz, CD <sub>3</sub> OD) d 119.66 ppm (CN)
Ex. 4	<sup>13</sup> C NMR (75 MHz, CD <sub>3</sub> OD) d 119.66 ppm (CN)
Ex. 10	<sup>13</sup> C NMR (75 MHz, D <sub>2</sub> O) d 121.69 ppm (CN)
Ex. 11	<sup>13</sup> C NMR (75 MHz, CDCl <sub>3</sub> ) d 118.31 ppm (CN)
Ex. 7D	<sup>13</sup> C NMR (75 MHz, CD <sub>3</sub> OD) d 119.63 ppm (CN)
Ex. 7E	<sup>13</sup> C NMR (75 MHz, CD <sub>3</sub> OD) d 119.64 ppm (CN)
Ex. 13	<sup>13</sup> C NMR (75 MHz, D <sub>2</sub> O) d 121.52 ppm (CN)
Ex. 14	<sup>13</sup> C NMR (75 MHz, D <sub>2</sub> O) d 121.52 ppm (CN)

The compounds of the invention in free form or in pharmaceutically acceptable acid addition salt form, hereinafter briefly named **"the agents of the invention"**, in particular, the compounds of formula I in free form or in pharmaceutically acceptable acid addition salt form, possess pharmacological activity. They are therefore indicated for use as pharmaceuticals.

In particular, they inhibit DPP-IV. This activity may be demonstrated employing the **Caco-2 DPP-IV assay**, which measures the ability of test compounds to inhibit DPP-IV activity from human colonic carcinoma cell extracts. The human colonic carcinoma cell line Caco-2 can be obtained from the American Type Culture Collection (ATCC HTB 37). Differentiation of the cells to induce DPP-IV expression is accomplished as described by Reisher et al. in Proc.Natl.Acad.Sci.USA 90 (1993) 5757-5761. Cell extract is prepared from cells solubilized in 10 mM Tris-HCl, 0.15 M NaCl, 0.04 t.i.u. (trypsin inhibitor unit) aprotinin, 0.5% non-ionic detergent P40, pH 8.0, which is centrifuged at 35 000 g for 30 min at 4°C to remove cell debris. The assay is conducted by adding 20 mg solubilized Caco-2 protein, diluted to a final volume of 125 µl in assay buffer (25 mM Tris-HCl pH 7.4, 140 mM NaCl, 10 mM KCl, 1% bovine serum albumin) to microtiter plate wells. The reaction is initiated by adding 25 µl of 1 mM substrate (H-Alanine-Proline-pNA; pNA is *p*-nitroaniline). The reaction is run at room temperature for 10 minutes after which time a 19 µl volume of 25% glacial acetic acid is added to stop the reaction. Test compounds are typically added as 30 µl additions and the assay buffer volume is reduced to 95 µl. A standard curve of free *p*-nitroaniline is generated using 0-500 µM solutions of free pNA in assay buffer. The curve generated is linear and is used for interpolation of substrate consumption (catalytic activity in nmoles substrate cleaved /min). The endpoint is determined by measuring absorbance at 405 nm in a Molecular Devices UV Max microtiter plate reader. The potency of the test compounds as DPP-IV inhibitors, expressed as IC<sub>50</sub>, is calculated from 8-point, dose-response curves using a 4-parameter logistic function.

In the above test, IC<sub>50</sub> values of from about 10 nM to about 900 nM are obtained with the agents of the invention, e.g. 22 nM for the agent of Example 3.

The DPP-IV inhibition may also be demonstrated by measuring the effects of test compounds on DPP-IV activity in human and rat plasma employing a modified version of the assay described by Kubota et al. in Clin.Exp.Immunol. 89 (1992) 192-197. Briefly, five µl of plasma are added to 96-well flat-bottom microtiter plates (Falcon), followed by the addition

of 5 ml of 80 mM  $\text{MgCl}_2$  in incubation buffer (25 mM HEPES, 140 mM NaCl, 1 % RIA-grade BSA, pH 7.8). After a 5 min incubation at room temperature, the reaction is initiated by the addition of 10 ml of incubation buffer containing 0.1 mM substrate (H-Glycine-Proline-AMC; AMC is 7-amino-4-methylcoumarin). The plates are covered with aluminum foil (or kept in the dark) and incubated at room temperature for 20 min. After the 20 min reaction, fluorescence is measured using a CytoFluor 2350 fluorimeter (Excitation 380 nm Emission 460 nm; sensitivity setting 4). Test compounds are typically added as 2 ml additions and the assay buffer volume is reduced to 13 ml. A fluorescence-concentration curve of free AMC is generated using 0-50 mM solutions of AMC in assay buffer. The curve generated is linear and is used for interpolation of substrate consumption (catalytic activity in nmoles substrate cleaved/min). As with the previous assay, the potency of the test compounds as DPP-IV inhibitors, expressed as  $\text{IC}_{50}$ , is calculated from 8-point, dose-response curves using a 4 parameter logistic function.

In the above assay,  $\text{IC}_{50}$  values of from about 7 nM to about 2000 nM are obtained in human plasma, and of from about 3 nM to about 400 nM in rat plasma, e.g., for the agent of Example 3, of 7 nM in human and 6 nM in rat plasma, respectively.

In view of their ability to **inhibit DPP-IV**, the agents of the invention are indicated for use in **treating conditions mediated by DPP-IV**. It is expected that the compounds disclosed herein are useful in the treatment of **non-insulin-dependent diabetes mellitus, arthritis, obesity, and osteoporosis such as calcitonin-osteoporosis**. The agents of the invention improve early insulin response to an oral glucose challenge and, therefore, are particularly indicated for use in treating **non-insulin-dependent diabetes mellitus and further conditions of impaired glucose tolerance (IGT)**.

The ability of the agents of the invention to improve early insulin response to an oral glucose challenge may e.g. be measured in insulin resistant rats according to the following method:

Male Sprague-Dawley rats that have been fed a high fat diet (saturated fat = 57 % calories) for 2-3 weeks are fasted for approximately 2 hours on the day of testing, divided into groups of 8-10, and dosed orally with 10 mmol/kg of the test compounds in carboxymethylcellulose (CMC). An oral glucose bolus of 1 g/kg is administered 30 min after

the test compound directly into the stomach of the test animals. Blood samples, obtained at various timepoints from chronic jugular vein catheters are analyzed for plasma glucose and immunoreactive insulin (IRI) concentrations, and plasma DPP-IV activity. Plasma insulin levels are assayed by a double antibody radioimmunoassay (RIA) method using a specific anti-rat insulin antibody from Linco Research (St. Louis, MO, USA). The RIA has a lower limit of detection of 0.5 mU/ml with intra- and inter-assay variations of less than 5%. Data are expressed as % increase of the mean of the control animals.

It was found that upon oral administration, each of the compounds tested amplified the early insulin response which led to an improvement in glucose tolerance in the insulin resistant test animals. The following results were obtained:

Compound	Increase of insulin response at 10 mmol/kg
Ex. 1	61 %
Ex. 3	66 %
Ex. 5	108 %
Ex. 8	144 %
Ex. 12	59 %

The precise dosage of the agents of the invention to be employed for treating conditions mediated by DPP-IV inhibition depends upon several factors, including the host, the nature and the severity of the condition being treated, the mode of administration and the particular compound employed. However, in general, conditions mediated by DPP-IV inhibition are effectively treated when an agent of the invention is administered enterally, e.g. orally, or parenterally, e.g. intravenously, preferably orally, at a daily dosage of from about 0.002 mg/kg to about 5 mg/kg, preferably of from about 0.02 mg/kg to about 2.5 mg/kg body weight or, for most larger primates, a daily dosage of from about 0.1 mg to about 250 mg, preferably from about 1 mg to about 100 mg. A typical oral dosage unit is from about 0.01 mg/kg to about 0.75 mg/kg, one to three times a day. Usually, a small dose is administered initially and the dosage is gradually increased until the optimal dosage for the host

under treatment is determined. The upper limit of dosage is that imposed by side effects and can be determined by trial for the host being treated.

The agents of the invention may be combined with one or more pharmaceutically acceptable carriers and, optionally, one or more other conventional pharmaceutical adjuvants and administered enterally, e.g. orally, in the form of tablets, capsules, caplets, etc., or parenterally, e.g. intravenously, in the form of sterile injectable solutions or suspensions. The enteral and parenteral compositions may be prepared by conventional means.

The agents of the invention may be formulated into enteral and parenteral pharmaceutical compositions containing an amount of the active substance that is effective for treating conditions mediated by DPP-IV, such compositions in unit dosage form and such compositions comprising a pharmaceutically acceptable carrier.

Those agents of the invention which are e.g. of formula I may be administered in enantiomerically pure (S) form (e.g.  $\geq 98\%$ , preferably  $\geq 99\%$  pure) or together with the other enantiomer, e.g. in racemic form. The above dosage ranges are based on the compounds of formula I (excluding the amount of R enantiomer).


The invention thus also comprises **an agent of the invention**, in particular, a compound of formula I as defined above, in free form or in pharmaceutically acceptable acid addition salt form, **for use as a pharmaceutical**. It further includes a **pharmaceutical composition** comprising an agent of the invention, in particular a compound of formula I as defined above, in free form or in pharmaceutically acceptable acid addition salt form, together with at least one pharmaceutically acceptable carrier or diluent. It further comprises the use of an agent of the invention, in particular, a compound of formula I as defined above, in free form or in pharmaceutically acceptable acid addition salt form **in the preparation of a medicament** for inhibiting DPP-IV or treating conditions mediated by DPP-IV, by a process comprising mixing an agent of the invention with a pharmaceutically acceptable carrier or diluent. It further provides a **method of inhibiting DPP-IV, or of treating conditions mediated by DPP-IV**, which comprises administering to a patient in need of such treatment a therapeutically effective amount of a compound of the invention, in particular, of formula I in free form or in pharmaceutically acceptable acid addition salt form.

The agents of Examples 1, 3, 5, 8 and 12 are the preferred agents of the invention, particularly those of Examples 1, 3, 5 and 12, preferably in hydrochloride acid addition salt form, especially the agent of Example 3, namely 1-[2-[(5-cyanopyridin-2-yl)amino]-ethylamino]acetyl-2-cyano-(S)-pyrrolidine, preferably in dihydrochloride acid addition salt form. It has been determined that in hydrochloride form they have an  $IC_{50}$  value in the Caco-2 DPP-IV assay of, respectively, 36, 22, 26, 8 and 279 nM, and in the modified Kubota assay above, an  $IC_{50}$  value for, respectively, human and rat plasma DPP-IV, of 27 and 22 nM (Example 1); 7 and 6 nM (Example 3); 37 and 18 nM (Example 5); 12 and 11 nM (Example 8); and 95 and 38 nM (Example 12). It is, therefore, indicated that for the above uses the compounds of Examples 1, 3, 5, 8 and 12 may be administered to larger mammals, for example humans, by similar modes of administration at similar dosages than conventionally employed with metformin.

**Claims:**

1. An N-(N'-substituted glycy)-2-cyanopyrrolidine.

2. A compound of formula I:



wherein R is:

a)  $R_1R_{1a}N(CH_2)_m$ - wherein

$R_1$  is a pyridinyl or pyrimidinyl moiety optionally mono- or independently disubstituted with  $(C_{1-4})$ alkyl,  $(C_{1-4})$ alkoxy, halogen, trifluoromethyl, cyano or nitro; or phenyl optionally mono- or independently disubstituted with  $(C_{1-4})$ alkyl,  $(C_{1-4})$ alkoxy or halogen;

$R_{1a}$  is hydrogen or  $(C_{1-8})$ alkyl; and

m is 2 or 3;

b)  $(C_{3-12})$ cycloalkyl optionally monosubstituted in the 1-position with  $(C_{1-3})$ hydroxyalkyl;

c)  $R_2(CH_2)_n$ - wherein either

$R_2$  is phenyl optionally mono- or independently di- or independently trisubstituted with  $(C_{1-4})$ alkyl,  $(C_{1-4})$ alkoxy, halogen or phenylthio optionally monosubstituted in the phenyl ring with hydroxymethyl; or is  $(C_{1-8})$ alkyl; a [3.1.1]bicyclic carbocyclic moiety optionally mono- or plurisubstituted with  $(C_{1-8})$ alkyl; a pyridinyl or naphthyl moiety optionally mono- or independently disubstituted with  $(C_{1-4})$ alkyl,  $(C_{1-4})$ alkoxy or halogen; cyclohexene; or adamantyl; and

n is 1 to 3; or

$R_2$  is phenoxy optionally mono- or independently disubstituted with  $(C_{1-4})$ alkyl,  $(C_{1-4})$ alkoxy or halogen; and

n is 2 or 3;

d)  $(R_3)_2CH(CH_2)_2$ - wherein each  $R_3$  independently is phenyl optionally mono- or independently disubstituted with  $(C_{1-4})$ alkyl,  $(C_{1-4})$ alkoxy or halogen;



-23-

- e)  $R_4(CH_2)_p$ - wherein  $R_4$  is 2-oxopyrrolidinyl or  $(C_{2-4})$ alkoxy and  
p is 2 to 4;
- f) **isopropyl** optionally monosubstituted in 1-position with  $(C_{1-3})$ hydroxyalkyl;
- g)  $R_5$  wherein  $R_5$  is: indanyl; a pyrrolidinyl or piperidinyl moiety optionally substituted with benzyl; a [2.2.1]- or [3.1.1]bicyclic carbocyclic moiety optionally mono- or plurisubstituted with  $(C_{1-8})$ alkyl; adamantyl; or  $(C_{1-8})$ alkyl optionally mono- or independently plurisubstituted with hydroxy, hydroxymethyl or phenyl optionally mono- or independently disubstituted with  $(C_{1-4})$ alkyl,  $(C_{1-4})$ alkoxy or halogen;  
in free form or in acid addition salt form,

3. A compound according to claim 2 (a **compound Ip**) wherein R is  $R^P$ , which is:

- a)  $R_1^P NH(CH_2)_2$ - wherein  $R_1^P$  is a pyridinyl or pyrimidinyl moiety optionally mono- or independently disubstituted with halogen, trifluoromethyl, cyano or nitro;
- b)  $(C_{3-7})$ cycloalkyl optionally monosubstituted in 1-position with  $(C_{1-3})$ hydroxyalkyl;
- c)  $R_2^P(CH_2)_2$ - wherein  $R_2^P$  is phenyl optionally mono- or independently di- or independently trisubstituted with halogen or  $(C_{1-3})$ alkoxy;
- d)  $(R_3^P)_2CH(CH_2)_2$ - wherein each  $R_3^P$  independently is phenyl optionally monosubstituted with halogen or  $(C_{1-3})$ alkoxy;
- e)  $R_4(CH_2)_3$ - wherein  $R_4$  is as defined above; or
- f) **isopropyl** optionally monosubstituted in 1-position with  $(C_{1-3})$ hydroxyalkyl;  
in free form or in acid addition salt form.

4. A compound according to claim 2 (a **compound Is**), wherein R is  $R^S$ , which is:

- a)  $R_1^S R_{1a}^S (CH_2)_{ms}$ - wherein  $R_1^S$  is pyridinyl optionally mono- or independently disubstituted with chlorine, trifluoromethyl, cyano or nitro; pyrimidinyl optionally monosubstituted with chlorine or trifluoromethyl; or phenyl;  
 $R_{1a}^S$  is hydrogen or methyl; and  
ms is 2 or 3;
- b)  $(C_{3-12})$ cycloalkyl optionally monosubstituted in 1-position with hydroxymethyl;

c)  $R_2^s(CH_2)_{ns}$ - wherein either

$R_2^s$  is phenyl optionally mono- or independently di- or independently trisubstituted with halogen, alkoxy of 1 or 2 carbon atoms or phenylthio monosubstituted in the phenyl ring with hydroxymethyl;  $(C_{1-6})$ alkyl; 6,6-dimethylbicyclo[3.1.1]hept-2-yl; pyridinyl; naphthyl; cyclohexene; or adamantyl; and ns is 1 to 3; or  $R_2^s$  is phenoxy; and ns is 2;

d) (3,3-diphenyl)propyl;

e)  $R_4^s(CH_2)_{ps}$  wherein  $R_4^s$  is 2-oxopyrrolidin-1-yl or isopropoxy and ps is 2 or 3;

f) isopropyl optionally monosubstituted in 1-position with hydroxymethyl;

g)  $R_5^s$  wherein  $R_5^s$  is: indanyl; a pyrrolidinyl or piperidinyl moiety optionally N-substituted with benzyl; bicyclo[2.2.1]hept-2-yl; 2,6,6-trimethylbicyclo[3.1.1]hept-3-yl; adamantyl; or  $(C_{1-8})$ alkyl optionally mono- or independently disubstituted with hydroxy, hydroxymethyl or phenyl;

in free form or in acid addition salt form.

5. The compound according to claim 2 wherein R is 2-[(5-cyanopyridin-2-yl)amino]ethyl, i.e. 1-[2-[(5-cyanopyridin-2-yl)amino]ethylamino]acetyl-2-cyano-(S)-pyrrolidine, in free form or in acid addition salt form, especially in dihydrochloride acid addition salt form, or a compound according to claim 2 which is of formula I wherein R is either


- 2-[(5-chloropyridin-2-yl)amino]ethyl, or
- (1-hydroxymethyl)cyclopent-1-yl, or
- 2-[(5-nitropyridin-2-yl)amino]ethyl, or
- 3-(isopropoxy)propyl,

in free form or in acid addition salt form.

6. A process for the preparation of a compound according to claim 1 which comprises coupling a reactive (2-cyanopyrrolidino)carbonylmethylene compound with an appropriate substituted amine or, for the preparation of a compound according to claim 2, which comprises

-25-

reacting a compound of formula II



wherein X is a reactive group,

with a compound of formula III



wherein R is as defined in claim 2,

and recovering the resultant compound in free form or in acid addition salt form.

7. A pharmaceutical composition comprising a compound according to claim 1 in free form or in pharmaceutically acceptable acid addition salt form, together with at least one pharmaceutically acceptable carrier or diluent.

8. A compound according to claim 1 in free form or in pharmaceutically acceptable acid addition salt form, for use as a pharmaceutical.

9. Use of a compound according to claim 1 in free form or in pharmaceutically acceptable acid addition salt form in the preparation of a medicament for inhibiting DPP-IV or treating conditions mediated by DPP-IV.

10. A method of inhibiting DPP-IV, or of treating a condition mediated by DPP-IV, which comprises administering a therapeutically effective amount of a compound according to claim 1 in free form or in pharmaceutically acceptable acid addition salt form to a patient in need of such treatment.

**THIS PAGE BLANK (USPTO)**



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

International Patent Classification <sup>6</sup> :  
A07D 207/16, 401/12, 403/12, A61K  
31/40, 31/44, 31/505

A3

(11) International Publication Number: WO 98/19998

(43) International Publication Date: 14 May 1998 (14.05.98)

(21) International Application Number: PCT/EP97/06125

(22) International Filing Date: 5 November 1997 (05.11.97)

(30) Priority Data:  
08/746,295 7 November 1996 (07.11.96) US(71) Applicant (for all designated States except US): NOVARTIS  
AG [CH/CH]; Schwarzwaldallee 215, CH-4058 Basel (CH).

(72) Inventor; and

(75) Inventor/Applicant (for US only): VILLHAUER, Edwin,  
Bernard [US/US]; 20 Dorothy Drive, Morristown, NJ  
07960 (US).(74) Agent: ROTH, Bernhard, M.; Novartis AG, Patent- und  
Markenabteilung, Lichtstrasse 35, CH-4002 Basel (CH).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR,  
BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE,  
GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK,  
LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO,  
NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR,  
TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH,  
KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ,  
BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE,  
CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,  
PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN,  
ML, MR, NE, SN, TD, TG).

## Published


With international search report.

Before the expiration of the time limit for amending the claims  
and to be republished in the event of the receipt of amendments.(88) Date of publication of the international search report:  
16 July 1998 (16.07.98)

(54) Title: N-SUBSTITUTED 2-CYANOPYRROLIDINES

## (57) Abstract

N-(N'-substituted glycyI)-2-cyanopyrrolidines, e.g. the  
compounds of formula (I) wherein R has various significances, are  
novel. They inhibit DPP-IV (dipeptidyl-peptidase-IV) activity.  
They are therefore indicated for use as pharmaceuticals in inhibiting  
DPP-IV and in the treatment of conditions mediated by DPP-IV,  
such as non-insulin-dependent diabetes mellitus, arthritis, obesity,  
osteoporosis and further conditions of impaired glucose tolerance.



**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 97/06125

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07D207/16 C07D401/12 C07D403/12 A61K31/40 A61K31/44  
A61K31/505

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 90 12005 A (YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD.) 18 October 1990 see page 39, compounds 19, 20, 22, 24 see abstract ---	1,7
A	EP 0 172 458 A (SUNTORY LTD.) 26 February 1986 see claims 1,4 ---	1,7
A	EP 0 115 639 A (HOECHST AG) 15 August 1984 see claim 1 ---	1
A	EP 0 132 580 A (HOECHST AG) 13 February 1985 see page 10, line 30 - page 11, line 3 -----	1



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

### \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*Z\* document member of the same patent family

Date of the actual completion of the international search

5 May 1998

Date of mailing of the international search report

25.05.98

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Hass, C

# INTERNATIONAL SEARCH REPORT

I national application No.

PCT/EP 97/06125

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 10  
because they relate to subject matter not required to be searched by this Authority, namely:  
Remark: Although claim 10  
is directed to a method of treatment of the human/animal  
body, the search has been carried out and based on the alleged  
effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such  
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all  
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment  
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report  
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is  
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest
- ☐ No protest accompanied the payment of additional search fees



# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 97/06125

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9012005 A	18-10-90	EP 0419683 A US 5118811 A	03-04-91 02-06-92
EP 172458 A	26-02-86	JP 1792858 C JP 4079334 B JP 61037764 A AU 575668 B AU 4559785 A US 4743616 A	14-10-93 15-12-92 22-02-86 04-08-88 06-02-86 10-05-88
EP 115639 A	15-08-84	DE 3300316 A AU 575306 B AU 2314684 A CA 1220213 A CA 1235128 C DK 6384 A DK 33196 A FI 840027 A,B JP 1799960 C JP 5006542 B JP 59144755 A JP 1873839 C JP 5070423 A JP 5083541 B JP 1882520 C JP 5078312 A JP 6010190 B PT 77924 B US 4684662 A	12-07-84 28-07-88 12-07-84 07-04-87 12-04-88 08-07-84 21-03-96 08-07-84 12-11-93 26-01-93 18-08-84 26-09-94 23-03-93 26-11-93 10-11-94 30-03-93 09-02-94 30-05-86 04-08-87
EP 132580 A	13-02-85	DE 3322530 A CA 1224792 A DK 306684 A FI 842522 A JP 60013756 A PT 78756 B US 4691022 A	10-01-85 28-07-87 24-12-84 24-12-84 24-01-85 22-07-86 01-09-87

**THIS PAGE BLANK (USPTO)**